Improving the quality of life and increasing the survival of patients with liver cirrhosis
European Foundation for the Study of Chronic Liver Failure
Travessera de Gràcia, 11
7th floor
08021 Barcelona

Team Leader

Prof. Dr. Dr. med. Jonel Trebicka
MICROB-PREDICT Coordinator, EF CLIF Research Associate, Head of Department Internal Medicine B (Münster, Germany)
Phone: +49 251 83 59 689
Send message

Team Members

Prof. Vicente Arroyo Perez (MD)
Phone: +34 932 271 400
Send message
Anna Bosch (PhD)
General Manager
Phone: +34 932 271 403
Send message
Lidia Garcia-Campmany (PhD)
Scientific Communications Manager
Phone: +34 932 271 407
Send message
Anna Curto Vilalta
Phone: +34 932 271 400
Send message
Cristina Sanchez Garrido
Data Manager
Phone: +34 932 271 400
Send message
Ferrán Aguilar
Phone: +34 717 771 627
Send message

Institute Presentation

The European Foundation for the Study of Chronic Liver Failure (EF CLIF) is a private nonprofit organization which mission is to promote research and education in chronic liver disease with the aim to contribute to improving the quality of life and to increase the survival of patients with cirrhosis.

EF CLIF has made pioneering efforts in conducting a series of large, international prospective studies that have been instrumental in reclassifying the trajectory of patients with chronic liver failure and led to the clinical, prognostic and pathophysiological definition of the syndrome referred to as “acute-on-chronic liver failure” (ACLF) characterized by acute decompensation of cirrhosis, severe systemic inflammation, organ failures, and high short-term mortality.


Since its foundation in 2009, the European Association for the Study of the Liver (EASL) Chair supports research activities through the EASL-CLIF Consortium, a network of 116 tertiary level university hospitals in 28 European countries. The EASL Chair promotes research in liver disease in Europe through a collaborative effort aimed at furthering the knowledge and understanding of the mechanisms underlying cirrhosis and its complications. The EASL-CLIF Consortium provides the framework to conduct ancillary studies and clinical trials that will lead to evaluate new therapies in cirrhosis, establish diagnostic criteria, and identify predictors for the design of new prognostic scores for acute-on-chronic liver failure—to improve the quality of life and survival of current and future patients with cirrhosis.

The Grifols Chair promotes translational studies across centers throughout Europe and North America within the framework of the European Network for Translational Research (ENTR) with 25 centers in 8 countries. The Grifols Chair promotes research aimed at characterizing the mechanisms underlying the presence of systemic inflammation in patients with decompensation of cirrhosis and its role in the development of acute-on-chronic liver failure.

More recently, the establishment of the Global Projects chapter has enabled to establish connections between healthcare professionals and experts over the world to further the understanding of the epidemiology and pathophysiology of ACLF. Through collaborative research, the Global Projects also aim to identify novel biomarkers and therapeutic targets in cirrhosis and develop guidelines that will contribute to minimize regulatory barriers and facilitate better outcomes and quality of life for patients with chronic liver disease worldwide.

EF CLIF also partners with industry to address unmet medical needs in cirrhosis and generate insights to drive innovative therapeutic solutions that can transform and revolutionize patient care.


EF CLIF is the coordinating institution of MICROB-PREDICT. It will deliver data from the CANONIC and PREDICT studies, samples from PREDICT, and participate in data analysis and validation. EF CLIF will also be the sponsor of the clinical ALB-TRIAL and participate in dissemination efforts, deliver crucial information about ethics and health economics in the centres of PREDICT, and contribute to cost-efficiency of tools and treatments.